These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9579299)
21. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198 [TBL] [Abstract][Full Text] [Related]
22. [Genetic polymorphism of the CYP2C subfamily]. Chiba K Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):15-21. PubMed ID: 9755458 [TBL] [Abstract][Full Text] [Related]
23. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. van der Weide J; Steijns LS; van Weelden MJ; de Haan K Pharmacogenetics; 2001 Jun; 11(4):287-91. PubMed ID: 11434505 [TBL] [Abstract][Full Text] [Related]
24. Frequencies of defective CYP2C19 alleles in a Hong Kong Chinese population: detection of the rare allele CYP2C19*4. Garcia-Barceló M; Chow LY; Kum Chiu HF; Wing YK; Shing Lee DT; Lam KL; Waye MM Clin Chem; 1999 Dec; 45(12):2273-4. PubMed ID: 10585366 [No Abstract] [Full Text] [Related]
25. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy. Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472 [TBL] [Abstract][Full Text] [Related]
26. CYP2C19 genetic mutations in North Indians. Lamba JK; Dhiman RK; Kohli KK Clin Pharmacol Ther; 2000 Sep; 68(3):328-35. PubMed ID: 11014415 [TBL] [Abstract][Full Text] [Related]
27. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825 [TBL] [Abstract][Full Text] [Related]
28. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Kubota T; Chiba K; Ishizaki T Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068 [TBL] [Abstract][Full Text] [Related]
29. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Sachdeo RC; Sachdeo SK; Levy RH; Streeter AJ; Bishop FE; Kunze KL; Mather GG; Roskos LK; Shen DD; Thummel KE; Trager WF; Curtin CR; Doose DR; Gisclon LG; Bialer M Epilepsia; 2002 Jul; 43(7):691-6. PubMed ID: 12102670 [TBL] [Abstract][Full Text] [Related]
30. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Goldstein JA; Blaisdell J Methods Enzymol; 1996; 272():210-8. PubMed ID: 8791779 [No Abstract] [Full Text] [Related]
31. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751 [TBL] [Abstract][Full Text] [Related]
33. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932 [TBL] [Abstract][Full Text] [Related]
34. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Donahue SR; Flockhart DA; Abernethy DR; Ko JW Clin Pharmacol Ther; 1997 Nov; 62(5):572-7. PubMed ID: 9390115 [TBL] [Abstract][Full Text] [Related]
35. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese. Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159 [TBL] [Abstract][Full Text] [Related]
38. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415 [TBL] [Abstract][Full Text] [Related]
39. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Balian JD; Sukhova N; Harris JW; Hewett J; Pickle L; Goldstein JA; Woosley RL; Flockhart DA Clin Pharmacol Ther; 1995 Jun; 57(6):662-9. PubMed ID: 7781266 [TBL] [Abstract][Full Text] [Related]
40. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Bajpai M; Roskos LK; Shen DD; Levy RH Drug Metab Dispos; 1996 Dec; 24(12):1401-3. PubMed ID: 8971149 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]